doi: 10.3389/fphar.2022.968226 Received 13 June 2022 Accepted 28 July 2022 Published 02 September 2022 Volume 13 - 2022 Edited by Dan-Qian Chen, Northwest University, China Reviewed by Milad Ashrafizadeh, Sabanc University, Turkey Yaser Hosny Ali Elewa, Zagazig University, Egypt Maria Russo, Institute of Food Sciences (CNR), Italy Updates Copyright 2022 Chen, Chen, Tang, Li, Liu, Lu and Gu
LPCAT3 inhibitors remodel the polyunsaturated phospholipid content of human cells and protect from ferroptosis
Mt cu hi c t ra l, c nn b sung thm Glutathione cho c th hay khng
External resources New England Journal of Medicine: Retatrutide Phase 2 trial results PMC meta-analysis: Comparative efficacy of GLP-1 receptor agonists Nature Medicine: Retatrutide for MASLD randomized Phase 2a trial Eli Lilly: TRIUMPH-4 Phase 3 retatrutide results press release New England Journal of Medicine: Tirzepatide versus semaglutide head-to-head trial In case I do not see you, good afternoon, good evening, and good night
Oxidative stress and decreased thiol level in patients with migraine: cross-sectional study
